Welcome to our dedicated page for Structure Therapeutics ADR SEC filings (Ticker: GPCR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Structure Therapeutics Inc. (NASDAQ: GPCR) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as a clinical-stage biopharmaceutical issuer. Structure Therapeutics is incorporated in the Cayman Islands and its American Depositary Shares, each representing three ordinary shares, are registered and listed on the Nasdaq Global Market under the symbol GPCR. The company files reports and current updates with the U.S. Securities and Exchange Commission in connection with its operations and capital markets activities.
Investors reviewing GPCR SEC filings will find current reports on Form 8-K that cover topics such as quarterly financial results, corporate updates, and outcomes of the annual general meeting of shareholders. For example, the company has furnished press releases announcing second and third quarter financial results and business updates via Form 8-K, and has reported shareholder voting results on director elections, auditor ratification, and advisory votes on executive compensation and say-on-frequency matters.
Structure Therapeutics also utilizes an automatic shelf registration statement on Form S-3 to conduct public offerings of American Depositary Shares and pre-funded warrants. Related prospectus supplements and offering documents are filed with the SEC and referenced in the company’s press releases. These filings provide details on the terms of upsized underwritten public offerings, gross proceeds, and the involvement of joint book-running managers and co-managers.
Through this filings page, users can monitor how Structure Therapeutics reports its financial condition, shareholder actions, and significant corporate events in its SEC submissions. Stock Titan enhances access to these documents with tools to quickly locate relevant 8-Ks and registration-related materials and to follow the company’s ongoing reporting history as a Nasdaq-listed clinical-stage biopharmaceutical company focused on oral small molecule GPCR-targeted therapies.
Structure Therapeutics Inc. chief medical officer Coll Crespo Blas reported a Form 4 showing a tax-related share disposition. On the vesting of a restricted share unit award, 11,826 Ordinary Shares were withheld by the company at $20.99 per share to cover income tax obligations. After this withholding transaction, Blas directly owned 204,981 Ordinary Shares. The footnotes explain that each American Depositary Share represents three Ordinary Shares.
Structure Therapeutics Inc. Chief Technology Officer Ma Yingli reported a tax-related share disposition tied to vesting of a restricted share unit award. On this transaction date, 11,313 Ordinary Shares were withheld by the company at a price of $20.99 per share to cover income tax obligations. After this tax-withholding disposition, Ma Yingli directly owned 107,391 Ordinary Shares. The company notes that each American Depositary Share represents three Ordinary Shares.
Structure Therapeutics Inc. chief scientific officer Xichen Lin reported a routine tax-related share transaction. On March 3, 2026, Lin had 18,735 Ordinary Shares withheld at $20.99 per share to cover income taxes triggered by the vesting of a restricted share unit award.
After this tax-withholding disposition, Lin directly owned 185,592 Ordinary Shares. The company notes that each American Depositary Share (ADS) represents three Ordinary Shares.
Structure Therapeutics Inc. reported an insider equity transaction by its Chief Financial Officer, Yoon JunMarch 3, 2026, 22,305 Ordinary Shares were disposed of through shares withheld by the company to cover income tax obligations tied to the vesting of a restricted share unit award at $20.99 per share, a tax-withholding disposition rather than an open-market sale. Following this, Yoon Jun directly held 1,297,571 Ordinary Shares and indirectly held 1,554,586 Ordinary Shares through The Yoon Family Trust. The company notes that its Ordinary Shares may be represented by ADSs, with each ADS equal to three Ordinary Shares.
Structure Therapeutics Inc.'s Chief Development Officer Ashley Hall reported several routine share movements. On March 3, 2026, Hall disposed of 4,836 Ordinary Shares at $20.99 per share to cover income taxes on a vesting restricted share unit award, leaving 107,481 Ordinary Shares directly owned.
Earlier, Hall acquired 225 American Depositary Shares (ADSs) on May 20, 2025 and 237 ADSs on November 20, 2025 through the company’s Employee Share Purchase Plan. Each ADS represents three Ordinary Shares and is convertible into Ordinary Shares at any time with no expiration date.
Structure Therapeutics Inc. CEO Raymond C. Stevens reported mixed share movements related primarily to tax withholding and existing holdings. On March 3, 2026, 53,454 Ordinary Shares were disposed of at $20.99 per share, withheld by the company to satisfy income tax obligations tied to a restricted share unit vesting.
After this tax-withholding disposition, Stevens directly held 1,141,376 Ordinary Shares. Indirectly, 1,554,586 Ordinary Shares and 12,000 American Depositary Shares (ADSs) are held by the Stevens 2001 Revocable Trust, where Raymond Stevens and Vivian Urena-Stevens act as co-trustees.
The filing also notes an earlier non-cash acquisition on November 20, 2025, when Stevens was granted 824 ADSs at
Structure Therapeutics is a clinical-stage biopharma company using structure-based design and computational chemistry to create oral small molecules that target GPCRs for chronic diseases, with a major focus on obesity and metabolic disorders.
The lead candidate, aleniglipron, an oral GLP‑1 receptor agonist, delivered placebo‑adjusted mean weight loss of 11.3% at 120 mg in the 36‑week Phase 2b ACCESS study and 15.3% at 240 mg in the exploratory ACCESS II study, with class‑consistent gastrointestinal side effects and no reported drug‑induced liver injury or QTc issues. Multiple Phase 2 and extension studies support moving into Phase 3 obesity trials in the second half of 2026.
The company is also advancing oral amylin receptor agonists ACCG‑2671 and ACCG‑3535 into Phase 1, plus early GIP and glucagon receptor programs, while retaining a broad GPCR pipeline. In December 2025, a subsidiary licensed certain non‑core GLP‑1 patents to Genentech and Roche for a $100 million upfront payment and future low single‑digit royalties.
Structure Therapeutics Inc. reported its fourth quarter and full-year 2025 results and provided a pipeline update focused on obesity treatments. Positive Phase 2 aleniglipron data showed significant weight loss across all doses, reaching up to 15.3% at 36 weeks, supporting advancement into Phase 3, which is expected to start in the second half of 2026.
The company reported cash, cash equivalents and short-term investments of $1.4 billion as of December 31, 2025, which it expects to fund operations and key clinical milestones through the end of 2028. Fourth quarter 2025 R&D expenses were $68.7 million and full-year R&D totaled $225.3 million, reflecting expanded clinical activity. Other license income of $100.0 million and $10.2 million of gains on sale of non-financial assets contributed to fourth quarter 2025 net income of $33.0 million, compared to a net loss of $36.5 million a year earlier. For full-year 2025, the company recorded a net loss of $141.2 million, compared to a net loss of $122.5 million in 2024.
Structure Therapeutics Inc. received an amended Schedule 13G showing that a group of Biotechnology Value Fund (BVF) entities and Mark N. Lampert collectively report beneficial ownership of 10,437,066 ordinary shares. This equals about 4.9% of the company’s 211,917,574 shares outstanding as of December 11, 2025.
The stake is primarily held through three BVF funds, with BVF owning 5,583,855 shares, BVF II holding 4,053,954 shares and Biotechnology Value Trading Fund OS LP holding 643,536 shares, largely via American Depositary Shares. The filers certify the position is passive and not for influencing control.
Deep Track Capital, LP, Deep Track Biotechnology Master Fund, Ltd. and David Kroin report beneficial ownership of 12,335,346 ordinary shares of Structure Therapeutics Inc., equal to 5.95% of the class as of December 31, 2025.
The ownership is calculated using 207,417,574 ordinary shares outstanding as of December 10, 2025, based on the issuer’s prospectus. The position includes 4,111,782 American Depositary Shares, each representing three ordinary shares. The filers certify the holdings are not for the purpose of changing or influencing control of the company.